Given its role in promoting cancer cell survival, metastasis, and chemoresistance, XBP1 represents a potential therapeutic target. Inhibitors of IRE1α, the enzyme responsible for XBP1 splicing, have shown promise in preclinical studies. These inhibitors can reduce XBP1 activation, thereby impairing the ability of cancer cells to manage ER stress. Additionally, disrupting XBP1 signaling can enhance the effectiveness of existing therapies, providing a synergistic approach to cancer treatment.
